{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:18:42Z","timestamp":1779297522993,"version":"3.51.4"},"reference-count":42,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s242984","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T21:24:18Z","timestamp":1588713858000},"page":"233-240","source":"Crossref","is-referenced-by-count":11,"title":["<p>Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements<\/p>"],"prefix":"10.2147","volume":"Volume 12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5829-3158","authenticated-orcid":true,"given":"Helen","family":"Phillips-Jackson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clive","family":"Hallam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niamh","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Gilman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Musgrave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","volume":"380","author":"Murray","year":"2012","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1080\/14656566.2017.1409722","volume":"18","author":"Dematteis","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1080\/10509674.2015.1043479","volume":"54","author":"Callaham","year":"2015","journal-title":"J Offender Rehabil"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"National Alliance to End Homelessness. Opioid abuse and homelessness. National Alliance to End Homelessness; 2016. Available from: https:\/\/endhomelessness.org\/resource\/opioid-abuse-and-homelessness\/.","DOI":"10.1093\/acprof:oso\/9780190463380.003.0008"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.jfda.2013.09.038","volume":"21","author":"Daley","year":"2013","journal-title":"J Food Drug Anal"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011117","author":"Nielsen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000320576","volume":"17","author":"St\u00f6ver","year":"2010","journal-title":"Eur Addict Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1080\/10826080802483936","volume":"44","author":"Anstice","year":"2009","journal-title":"Subst Use Misuse"},{"key":"ref9","first-page":"403","volume":"28","author":"Vigilant","year":"2004","journal-title":"Sage"},{"key":"ref10","unstructured":"European Medicines Agency. Buvidal Buprenorphine, summary of opinion (initial authorisation). 2018."},{"key":"ref11","unstructured":"European Medicines Agency. Buvidal - summary of product characteristics; 2018. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/buvidal-epar-product-information_en.pdf."},{"key":"ref12","unstructured":"European Medicines Agency. Assessment Report - Buvidal - International Non-Proprietary Name: buprenorphine; 2018. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/buvidal-epar-public-assessment-report_en.pdf."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s12325-016-0472-9","volume":"34","author":"Albayaty","year":"2017","journal-title":"Adv Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1001\/jamapsychiatry.2017.1874","volume":"74","author":"Walsh","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jsat.2017.04.008","volume":"78","author":"Haasen","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern Med"},{"key":"ref17","unstructured":"Institute for Clinical and Economic Review. Extended-release opioid agonists and antagonists for Medication- Assisted Treatment (MAT) of opioid use disorder: effectiveness and value. 2018."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/add.14636","volume":"114","author":"Frost","year":"2019","journal-title":"Addiction"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.2147\/PPA.S180641","volume":"12","author":"Gilman","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"ref20","unstructured":"England Public Health. United Kingdom drug situation: focal point annual report 2017. 2017. Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/713101\/Focal_Point_Annual_Report.pdf."},{"key":"ref21","unstructured":"England Public Health. Alcohol and drug treatment for adults: statistics summary 2017 to 2018. 2018."},{"key":"ref22","unstructured":"National Treatment Agency for Substance Misuse. JSNA support pack for commissioners of recovery in communities 2013 JSNA support pack for commissioners. 2013;(April)."},{"key":"ref23","unstructured":"National Audit Office. Public Health England\u2019s Grant to Local Authorities; 2014."},{"key":"ref24","first-page":"1","volume":"11","author":"Connock","year":"2007","journal-title":"Health Technol Assess"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Gibbons C, Jensen R Modelling the budgetary impact of treating opioid dependence in the English municipal setting. 2018.","DOI":"10.1016\/j.jval.2018.09.1680"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1080\/13696998.2017.1325744","volume":"20","author":"Kenworthy","year":"2017","journal-title":"J Med Econ"},{"key":"ref27","unstructured":"NHS. Amendments to the drug tariff April 2019; April 2019. Available from: https:\/\/www.nhsbsa.nhs.uk\/sites\/default\/files\/2019-03\/. Drug Tariff April 2019.pdf."},{"key":"ref28","unstructured":"Department of Health (England). Clinical Guidelines on Drug Misuse and Dependence Update 2017. London: Independent Expert Working Group; 2017."},{"key":"ref29","unstructured":"NHS. Drug tariff 2018. 2018."},{"key":"ref30","unstructured":"PSNC. Changes to oral liquid methadone fee arrangements FAQs \u2013 March 2013. 2013."},{"key":"ref31","unstructured":"Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group. Drug Misuse and Dependence: UK Guidelines on Clinical Management. London: Global and Public Health\/Population Health\/Healthy Behaviours\/25460; 2017."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.jsat.2010.07.009","volume":"39","author":"Pinto","year":"2010","journal-title":"J Subst Abuse Treat"},{"key":"ref33","unstructured":"Trial record. Clinical trial of CAM2038, long-acting subcutaneous buprenorphine injections for treatment of patients with opioid dependence. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02651584?term=NCT02651584&rank=1. Accessed May 24, 2019."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"A711","DOI":"10.1016\/j.jval.2017.08.1880","volume":"20","author":"Tiberg","year":"2017","journal-title":"Value Health"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"A711","DOI":"10.1016\/j.jval.2017.08.1879","volume":"20","author":"Jensen","year":"2017","journal-title":"Value Health"},{"key":"ref36","volume-title":"An Evidence Review of the Outcomes That Can Be Expected of Drug Misuse Treatment in England","year":"2017"},{"key":"ref37","unstructured":"National Institute for Health and Care Excellence. Evidence review opioid dependence: buprenorphine prolonged- release injection (Buvidal); 2019. Available from: https:\/\/www.nice.org.uk\/advice\/es19\/evidence\/evidence-review-pdf-6666819661."},{"key":"ref38","unstructured":"Methadone dispensing (FP10 and FP10MDA)."},{"key":"ref39","unstructured":"PSNC. Pharmaceutical services negotiating committee - fees and allowances; 2018. https:\/\/psnc.org.uk\/dispensing-supply\/endorsement\/fees-allowances\/. Accessed December 20, 2018.."},{"key":"ref40","unstructured":"National Institute for Health and Care Excellence (NICE). Costing statement: needle and syringe programmes; 2014. Available from: https:\/\/www.nice.org.uk\/guidance\/ph52\/resources\/ph52-needle-and-syringe-programmes-costing-statement2."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jval.2017.07.014","volume":"21","author":"Langham","year":"2018","journal-title":"Value Health"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cemconcomp.2014.07.014","author":"Curtis","year":"2017","journal-title":"Pers Social Serv Res Unit"}],"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=57908","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=57908","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T21:24:35Z","timestamp":1588713875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/budget-impact-analysis-of-the-introduction-of-injectable-prolonged-rel-peer-reviewed-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":42,"URL":"https:\/\/doi.org\/10.2147\/ceor.s242984","relation":{},"ISSN":["1178-6981"],"issn-type":[{"value":"1178-6981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}